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Summary Candida intermedia is rarely reported as a human pathogen. We report two cases of
catheter-related fungemia caused by C. intermedia which were treated successfully with
intravenous fluconazole and catheter removal. The isolates were identified by commercial
biochemical methods, oligonucleotide array, and partial sequencing analysis of rRNA genes.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
In recent decades, invasive candidiasis has emerged as an
important nosocomial infection.1 Among the more than 200
Candida species, only a few can cause human diseases.2
Candida intermedia is rarely reported as a human pathogen.
We report two patients, hospitalized in the same ward, who
had catheter-related C. intermedia fungemia within a 20-day
interval.
Case reports
A 99-year-old man (patient A) with gastric adenocarcinoma
had received a total gastrectomy with Billroth’s II anasto-
mosis in January 2007. He was admitted to the hospital in
early 2008 because of post-operative adhesion ileus. A broad-* Corresponding author. Tel.: +886 2 23123456x5355.
E-mail address: hsporen@ntu.edu.tw (P.-R. Hsueh).
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doi:10.1016/j.ijid.2009.03.015spectrum cephalosporin was given for fever and a suspected
intra-abdominal infection early in his hospital stay. Due to
prolonged poor oral intake, a Port-A-Cath (Smiths Industries
Medical Systems (SIMS), Deltec, Inc., St. Paul, MN, USA) was
inserted for parenteral nutrition. After the administration of
parenteral nutrition for two weeks, an episode of fever and
leukocytosis with left-shift developed. He had no respiratory
or urethral symptoms. A chest radiograph showed no pneu-
monia patch, and urinalysis was normal. Blood cultures from
the Port-A-Cath (isolate 1) and peripheral vein (isolate 2)
were both positive for yeasts. The species was identified as C.
intermedia. The Port-A-Cath was removed and culture of the
removed catheter tip was also positive for C. intermedia.
Intravenous fluconazole (400 mg every day) was adminis-
tered. His fever subsided, his white blood cell (WBC) count
decreased to the normal range, and C. intermedia fungemia
was eradicated after fluconazole treatment for two weeks.
A 37-year-old man (patient B) had a history of megacolon
and had received surgical intervention at birth. Short bowel
syndrome developed after surgery and thereafter hePublished by Elsevier Ltd. All rights reserved.
Figure 1 Random amplified polymorphic DNA (RAPD) patterns
of three Candida intermedia isolates generated by arbitrarily
primed PCR with four primers: upper panels, OPA3 and OPH15;
lower panels, ERIC1 and M13. M, 1-kb ladder marker (GIBCO BRL
Products, Gaithersburg, MD, USA); lanes 1 and 2, two isolates
from patient A; lane 3, one isolate from patient B; lanes 4—7,
isolates of Candida albicans, Candida glabrata, Candida tropi-
calis, and Candida parapsilosis, respectively, from four patients
with candidemia.
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central venous catheter. Over the past decades, he had
undergone replacement of the central venous catheter sev-
eral times due to catheter-related infections. One month
before this event, he had experienced an episode of cathe-
ter-related infection with Escherichia coli bacteremia, which
was successfully treated with an advanced-generation
cephem. In late March 2008, he had a high fever with chills.
No other specific symptoms or physical signs were noted. His
WBC count was within the normal range, but marked left-
shift was noted. A chest radiograph was normal. Blood cul-
tures from a peripheral vein (isolate 3) and a central venous
catheter (isolate 4) both yielded yeasts. Catheter-related
candidemia was highly suspected. The central venous cathe-
ter was replaced, but culture of the removed catheter tip was
not performed. Intravenous fluconazole (200 mg every day)
was administered. The two isolates in blood cultures were
identified as C. intermedia. His fever subsided and follow-up
blood cultures were negative.
Microbiology
The times to positivity of peripheral venous and central
venous blood cultures for the two patients were 10 h and
12 h, respectively, compatible with a diagnosis of catheter-
related fungemia. The four isolates grew well on CHROMOA-
gar (BBL Microbiology Systems, Cockeysville, MD, USA) with
purple colonies at 37 8C for 48 hours of incubation. On corn-
meal-Tween 80 agar (BBL Microbiology Systems), blastoconi-
dia, singly or in small clusters, with pseudohyphae were seen
at 37 8C for 48 h. These isolates were identified as C. inter-
media (bionumber 4156155675343371; probability, 97%; con-
fidence, excellent identification) by Vitek 2 Yeast cards
(bioMerieux Vitek, St. Louis, MO, USA). The isolates were
further identified by an oligonucleotide array assay as pre-
viously described3 and partial sequencing of rRNA genes.4 The
positive oligonucleotide array result and high percentage of
identity in the rRNA loci 5.8S—28S (98—100%), 18S—28S
(100%), and 28S (100%) confirmed the identification of C.
intermedia. Antifungal susceptibility testing of the isolates
was performed using the broth microdilution method, and
the results were interpreted according to the guidelines of
the Clinical and Laboratory Standards Institute (formerly the
National Committee for Clinical Laboratory Standards).5 Two
reference strains, Candida parapsilosis ATCC 22019 and Can-
dida krusei ATCC 6258, were used for quality control. The
minimum inhibitory concentrations (MICs) of the two isolates
were the same, with 1 mg/ml for fluconazole, 4 mg/ml for
5-fluorocytosine, 0.06 mg/ml for voriconazole, 0.125 mg/ml
for itraconazole, and 0.5 mg/ml for amphotericin B.
Because the two C. intermedia fungemias developed in
the same ward over a short interval (3 weeks), molecular
typingwas performed to rule out the possibility of nosocomial
infection. Random amplified polymorphic DNA (RAPD) pat-
terns of the three isolates (isolates 1—3) were generated by
arbitrarily primed PCR (APPCR) as described previously.6 Four
oligonucleotide primers were used: ERIC1 (50-GTGAATCCC-
CAGGAGCTTACAT-30), M13 (50-TTATGTAAAACGACGGCCAGT-
30), OPA3 (50-AGTCAGCCAC-30), and OPH15 (50-AATGGCG-
CAG-30) were purchased from Operon Technologies, Inc.
(Alameda, CA, USA). The RAPD patterns of the two isolateswere different indicating that they belonged to different
strains (Figure 1).
Discussion
Candida species are an important cause of nosocomial blood-
stream infections and are associated with high mortality.1,7
Although more than 200 species of Candida have been iden-
tified, only a few cause diseases in humans.2 The great
majority of Candida infection is caused by Candida albicans.
However, there is some evidence that non-albicans infections
may be increasing.8,9 C. intermedia, a rare non-albicans
Candida, is known to be part of the microflora on the surface
of cheese and in the human oropharyngeal cavity,10—12 and
has seldom been linked to human disease. This organism has
been reported in a case series of fungemia, but no detailed
clinical andmicrobiological information has been provided.13
To our knowledge, this is the first case report to describe
clinical features and microbiological characteristics of C.
intermedia fungemia in the English literature. The reasons
why these two reported patients were susceptible to C.
intermedia infection are not clear. The chronic malnutrition
status and long-term use of parenteral nutrition or intrave-
nous catheter might have contributed to their susceptibility
to C. intermedia infection.
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a central venous catheter, abdominal surgery, parenteral
nutrition, malignancy, and renal failure requiring hemodia-
lysis, are considered to be associated with candidemia.1,14 In
the two reported cases, the C. intermedia fungemia was
associated with central venous catheters and the use of
parenteral nutrition. In addition, the two reported patients
had also received broad-spectrum antibiotics within 30 days
before the onset of fungemia. Some Candida species, such as
C. parapsilosis, have been considered to have a strong
association with catheter-related infections.15,16 C. inter-
media may be another Candida species that tends to cause
catheter-related infections. However, more reports are
needed to support this presumption.
The clinical presentation of the C. intermedia fungemia in
the two cases, including fever, leukocytosis or left-shift
differential count, was non-specific. The disease course
was relatively benign and no shock or irreversible end-organ
damage was noted. Even in an immunocompromised host,
such as the elderly patient with advanced cancer in the first
case (patient A), the C. intermedia fungemia was cured by
catheter removal and two weeks of fluconazole therapy.
Fluconazole resistance is one of the great concerns in treat-
ing patients with fungemia, especially where prompt sus-
ceptibility testing is not available. In this report, the C.
intermedia isolates were susceptible to the five tested anti-
fungal agents, and fluconazole had potent in vitro activity
against the isolates. 5,17,18
In summary, this is the first case report of human blood-
stream infections caused by C. intermedia. It raises the
possibility that C. intermedia may be a causative pathogen
of catheter-related fungemia in patients with long-term
parenteral nutrition or intravenous catheters over a long
period.
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